Credit: TB CABA comment authored by Dr. Jennifer Furin (Harvard Medical School) and Rosa Herrera (Autonomous University of Durango; emeritus TB CAB member), reflects on the potential challenges of a prespecified exploratory analysis evaluating the efficacy and safety of 8-week treatment regimens for rifampicin-susceptible pulmonary TB (TRUNCATE-TB trial), published in The Lancet Infectious Diseases.
The authors remind us that “…regimen duration is not the only characteristic associated with more tolerable TB treatment. Key among treatment characteristics that people with TB value is durable cure, and taking a regimen that could require repeated courses of treatment might not be a viable strategy for many of them. Quality of care is as important as duration of treatment. While the enthusiasm for shorter regimens is understandable, it should not override what people with TB say they need most: holistic therapy that acknowledges their humanity at every step.”
Access the full comment here.
* Image: Dr. Jennifer Furin (left), Rosa Herrera (right)
For more TB updates, check out the TB CAB Weekly Newsletter (Issue #29, 29 September 2025).
The newsletter is brought to you by the Global TB Community Advisory Board (TB CAB) with the support of Treatment Action Group (TAG) and EATG. Subscribe to the newsletter here.
Source : TB CAB
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.